arrow
B

Bahadır Köylü

Koc University
H指数:5
被引数:100

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Triggering receptors expressed on myeloid cells (TREM-1) and TREM-2 as predictors of pathological complete response to neoadjuvant therapy in triple-negative breast cancer

髓系细胞表达触发受体(TREM-1)和TREM-2作为三阴性乳腺癌新辅助治疗病理完全缓解的预测因子

2026-09-210
OAAI
Externally validated explainable machine learning for postoperative recurrence prediction in early-stage NSCLC

基于外部验证的可解释机器学习在早期非小细胞肺癌术后复发预测中的应用

2026-09-120
OA
Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma

晚期尿路上皮癌二线化疗的真实世界疗效

2026-09-030
OA
First-Line Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey

一线度伐利尤单抗–特瑞普利单抗治疗晚期肝细胞癌:来自土耳其的真实世界数据

2026-08-020
OA
Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

在EGFR突变NSCLC发生SCLC转化后,联合免疫疗法与化疗可能改善生存:一项多中心真实世界研究

2026-08-010
PRE
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

真实世界结局与进展模式:土耳其国家肿瘤学组研究——一线奥希替尼治疗晚期EGFR突变非小细胞肺癌患者的疗效

Cancers
IF4.4
2026-06-180
OA
Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study

晚期软组织肉瘤接受曲贝替定治疗后营养和炎症评分的预后价值:一项多中心研究

2026-04-230
OA
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

brigatinib 在晚期ALK阳性NSCLC中的真实世界有效性与安全性:土耳其肿瘤学组进行的一项全国多中心研究

2026-02-110
PRE
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

与健康相关的生活质量和免疫检查点抑制剂治疗长期存活者的心理社会结局:一项全国性多中心研究

2025-12-100
OA